First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

PURPOSE: This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351. PATIENTS AND METHODS: CPX-351 induction was administered on days 1, 3, and 5 by 90-minute infusion to 48 relapsed or refractory patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Feldman, Eric J., Lancet, Jeffrey E., Kolitz, Jonathan E., Ritchie, Ellen K., Roboz, Gail J., List, Alan F., Allen, Steven L., Asatiani, Ekatherine, Mayer, Lawrence D., Swenson, Christine, Louie, Arthur C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4520927/
https://ncbi.nlm.nih.gov/pubmed/21282541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.5961
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados